 Vaccines, Synthetic
"Vaccines, Synthetic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
| Descriptor ID |
D014614
|
| MeSH Number(s) |
D12.776.828.868 D20.215.894.865 D23.050.865
|
| Concept/Terms |
Vaccines, Synthetic- Vaccines, Synthetic
- Synthetic Vaccines
- Synthetic Immunogens
- Immunogens, Synthetic
Molecular Vaccines- Molecular Vaccines
- Vaccines, Molecular
- Vaccines, Chemical
- Chemical Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Synthetic".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Synthetic".
This graph shows the total number of publications written about "Vaccines, Synthetic" by people in this website by year, and whether "Vaccines, Synthetic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 1 | 3 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2007 | 1 | 1 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 2 | 0 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 1 | 2 | | 2019 | 2 | 3 | 5 | | 2020 | 1 | 3 | 4 | | 2021 | 1 | 12 | 13 | | 2022 | 0 | 15 | 15 | | 2023 | 0 | 2 | 2 | | 2024 | 0 | 1 | 1 | | 2025 | 0 | 2 | 2 | | 2026 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Vaccines, Synthetic" by people in Profiles.
-
Belongia EA, Kieke BA, Hanson KE, McClure DL, Boyce TG, Daley MF, DeSilva MB, Hurley LP, Irving SA, Jackson LA, Duffy J, McNeil MM, Sundaram ME. Retrospective cohort study of mRNA COVID-19 vaccine-associated enhanced disease in the Vaccine Safety Datalink, 2021-23. Hum Vaccin Immunother. 2026 Dec; 22(1):2681305.
-
Bansal A, Stoffel EM, Lim R, Stanich PP, Patel SG, Burke CA, Hall MJ, Singh A, Boardman LA, Samadder NJ, Ballestar V, Muller C, Scott AJ, Benante KA, Xu Y, Eickhoff J, Hyun M, Zaborek J, Aquila L, Umar A, Szabo E, Della'Zanna G, Richmond E, Bengtson L, Schlom J, Donahue RN, Toney NJ, Horn LA, Palena C, Gulley JL, Samaddar S, Moore DF, Sharma P, Madan R, Hurley KE, Soon-Shiong P, Gabitzsch E, Sender L, Brenner D, Schuetze S, Djuric Z, Barroilhet LM, Thompson P, Bauman J, Khan SA, Vilar E. Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet). Front Immunol. 2026; 17:1809281.
-
Hawkins JA, Curtis JR, Weinberg A, Siegel SAR, Huffstutter JE, Loveless J, Gharib S, Reddy S, Sinha J, Ridley D, Messaoudi I, Park JK, Lee EB, Winthrop KL. Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial. Ann Rheum Dis. 2026 May; 85(5):787-796.
-
Johnson MJ, Crotteau M, Ghosh D, Vu T, Trinity L, Marches R, Ucar D, Levin MJ, Weinberg A. The recombinant zoster vaccine induces trained immunity in monocytes through persistent downregulation of TGFß. PLoS Pathog. 2025 Dec; 21(12):e1013759.
-
Coleman HJ, Rauch A, Langsfeld E, Anderson K, Parlikar U, Funke HH, Garcea RL, Randolph TW. Lipid-free, thermostable mRNA vaccines prepared using atomic layer deposition. J Pharm Sci. 2026 Feb; 115(2):104066.
-
Zerbo O, Bartlett J, Fireman B, Lewis N, Goddard K, Dooling K, Duffy J, Glanz J, Naleway A, Donahue JG, Klein NP. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. Ann Intern Med. 2024 02; 177(2):189-195.
-
Laing KJ, Ford ES, Johnson MJ, Levin MJ, Koelle DM, Weinberg A. Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity. J Clin Invest. 2023 12 01; 133(23).
-
Weinberg A, Scott Schmid D, Leung J, Johnson MJ, Miao C, Levin MJ. Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines. J Infect Dis. 2023 11 11; 228(10):1367-1374.
-
Callegaro A, Burny W, Hervé C, Hyung Kim J, Levin MJ, Zahaf T, Cunningham AL, Didierlaurent AM. Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine. J Infect Dis. 2022 11 28; 226(11):1943-1948.
-
Liu H, Wei P, Aviszus K, Zhang Q, Linderberger J, Yang J, Liu J, Chen Z, Waheed H, Reynoso L, Downey GP, Frankel SK, Kappler JW, Marrack P, Zhang G. The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity. Int J Mol Sci. 2022 Sep 26; 23(19).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|